Spyre Therapeutics (NASDAQ: SYRE) Chief Executive Officer Turtle Cameron disposed of 15,000 shares of the company's common stock on April 1, 2026, per a Form 4 filing with the Securities and Exchange Commission.
The aggregate proceeds from the transactions totaled approximately $739,912. The sales were executed across multiple trades with per-share prices spanning $48.64 to $50.50. In detail, 12,344 shares were sold at a weighted average price of $49.20, generating about $607,324, and a further 2,656 shares were sold at a weighted average price of $49.92, yielding roughly $132,600.
Following these dispositions, Cameron retains direct ownership of 627,540 shares of Spyre Therapeutics. The filing specifies the trades were carried out pursuant to a Rule 10b5-1 trading plan that Cameron adopted on June 20, 2025.
The insider selling comes while Spyre shares are trading close to their 52-week high of $51.06. At the time of the filing, the stock was quoted at $47.58, implying a market capitalization of approximately $3.74 billion. Analysts and tools referenced by the company note differing views on valuation; an InvestingPro analysis noted that the stock appears overvalued at current levels and referenced 14 additional InvestingPro Tips plus a Fair Value analysis to aid investor assessment.
Recent operational developments at Spyre have likely contributed to investor attention. The company moved up the timeline for its Phase 2 SKYWAY basket trial: enrollment in the rheumatoid arthritis sub-study of its SPY072 program was completed ahead of schedule, and topline data is now expected in the third quarter of 2026 instead of the previously anticipated fourth quarter. Beyond that sub-study, Spyre anticipates six proof-of-concept readouts across its SKYLINE and SKYWAY trials in 2026, covering indications in inflammatory bowel disease and rheumatic conditions.
Market research and sell-side commentary included in the filing narrative indicate positive reinforcement from several firms. BTIG reiterated a Buy rating on Spyre stock following a co-funding agreement between Royalty Pharma and Johnson & Johnson. Stifel raised its price target for Spyre to $92, citing potential advancements in inflammatory bowel disease treatments. Leerink Partners kept an Outperform rating, calling the accelerated trial timeline a constructive development. Guggenheim continued to list Spyre as a top pick for 2026.
The Form 4 filing provides a view into executive liquidity and ownership position while clinical catalysts and analyst coverage are shaping market interest. The sale itself was conducted under the pre-established 10b5-1 plan, which the filing notes was adopted mid-2025.
Contextual notes for investors
- The transaction was disclosed via Form 4 to the SEC and executed under a Rule 10b5-1 plan dated June 20, 2025.
- Spyre is advancing multiple Phase 2 efforts with an accelerated timeline for at least one sub-study and a schedule of six proof-of-concept readouts planned in 2026.
- Analyst coverage cited in the disclosure ranges from reiterated Buy and Outperform ratings to an increased price target, signaling divergent market perspectives on the programmatic and valuation outlook.